

Board of Directors (in Public)

Item: 6.1.2
Subject: Integrated Performance Committee BAF Key Issues
Date of Meeting: Tuesday 26th November 2019
Prepared by: Claire Wilson - Chief Finance Officer
Presented by: Karen O'Hagan - Integrated Performance Committee Chair
Meeting Held: 28th October 2019

Agenda Item	Lead Exec	Assurance Received	New/Emerging Risks	Actions/Comments
5.1	HK	Surgical activity recovery plan	Risk in relation to recurrent financial sustainability, currently being mitigated through a divisional action plan.	At Month 6 2019/20, clinical income is £2.5m behind plan with the main driver being the continued lower than plan levels of surgical activity. The Surgical Division presented a comprehensive analysis of the issues contributing to the position and set out the actions being taken to reduce the underperformance by the end of the year. Action plan to be implemented by the Division.
5.2 and 5.3	HK	Month 06 Performance Report	No change to current BAF	IPC reviewed current performance across full range of KPIs and noted key exceptions and mitigating actions including: <ul style="list-style-type: none"> - Continued pressures on the six week diagnostic target with performance slipping below 70 % in month, with an increasing backlog of patients. - Challenges delivering the surgical activity plan - A 52 week breach in month due to a late referral (52 weeks). Noted that performance will recover by the end of October 2019.

				<ul style="list-style-type: none"> - Patients waiting longer than 18 weeks continues to increase with the significant pressure being in Cardiology. The Division continues to work on capacity to reduce patient delays but there is a risk to the delivery of the Trust aggregate position. - One never event reported in month which has been subject to a separate update at the Board - Sickness remains a significant pressure for the Trust which is a focus of the Operational Board
5.4	CW	Month 06 Finance Report including CIP	No change to current BAF	<p>The Trust has been able to deliver its financial plan in the year to date given a £327k non-recurrent benefit from the delayed transfer of high cost devices to the zero cost national procurement programme. The single biggest factor in the adverse position is a significant underperformance on surgical activity.</p> <p>The Trust is forecasting delivery of its 'adjusted' control total of a £2,944k surplus despite the adverse variance on the divisional position. The single biggest contributor to this is an approximately £2.062m benefit on device income for the year; however, this is a non-recurrent benefit and so the adverse impact on the recurrent run rate will continue into 2020/21 until the recurrent position is recovered.</p>
5.5	CW	Draft Strategic Planning & 5 Year Capital Programme	No change to current BAF	<p>IPC received a paper describing the approach to strategic and operational planning for 2019/20.</p> <p>A draft plan was submitted to Cheshire and Merseyside Health and Social Care partnership on 13th of September 2019 which has been modelled using a number of national assumptions. Further work is ongoing with clinical teams and commissioners to refine the plan in support of a full submission in November 2019.</p>